Patent application EP15202582A (EP), filed 2015-12-23
Publication number: EP3184544A1
Title: GLYCOPROTEIN V INHIBITORS FOR USE AS COAGULANTS
Abstract: The present invention relates to an inhibitor of glycoprotein V (GPV) for use as a coagulant, and/or for use in the treatment or prevention of a hemorrhagic condition.
IPC codes: A61K  39/   395            A I
A61P   7/    04            A I
C07K  16/    28            A I
C07K  16/    36            A I
Claims: number: 1
text: An inhibitor of glycoprotein V (GPV) for use as a coagulant.
number: 2
text: An inhibitor of glycoprotein V (GPV) for use in the treatment or prevention of a hemorrhagic condition.
number: 3
text: The inhibitor for use according to claim 2, wherein said hemorrhagic condition is caused by a platelet disorder.
number: 4
text: The inhibitor for use according to claim 3, wherein said platelet disorder is characterized by a decreased number of platelets.
number: 5
text: The inhibitor for use according to any one of claims 2 to 4, wherein said hemorrhagic condition is selected from the group consisting of inflammatory bleeding, hemorrhagic stroke, excessive bleeding due to sepsis, excessive bleeding due to thrombocytopenia, excessive bleeding due to disseminated intravascular coagulation (DIC), excessive bleeding due to chemotherapy, excessive bleeding due to hemolytic-uremic syndrome, and excessive bleeding due to HIV infection.
number: 6
text: The inhibitor for use according to any one of the preceding claims, wherein said GPV is human GPV.
number: 7
text: The inhibitor for use according to any one of the preceding claims, wherein said inhibitor is an antibody directed against the extracellular domain of GPV, or a functional fragment or derivative of an antibody, said fragment or derivative being capable of binding to the extracellular domain of GPV.
number: 8
text: The inhibitor for use according to claim 7, wherein said antibody is a monoclonal antibody or a functional fragment or functional derivative thereof.
number: 9
text: The inhibitor for use according to any one of the preceding claims, wherein said inhibitor is a nucleic acid capable of reducing expression ofGP5 mRNA.
number: 10
text: The inhibitor for use according to any one of the preceding claims, wherein said inhibitor, upon administration to a subject, does not affect the number of platelets in said subject.
number: 11
text: The inhibitor for use according to any one of claims 2 to 10, wherein said inhibitor is used as a coagulant.
number: 12
text: The inhibitor for use according to any one of claims 2 to 11, wherein said treatment or prevention comprises administering to a subject, preferably to a human, a pharmaceutically effective amount of said inhibitor.
number: 13
text: The inhibitor for use according to claim 12, wherein said treatment or prevention further comprises administering to said subject a coagulant other than said inhibitor.
number: 14
text: The inhibitor for use according to claim 13, wherein said coagulant other than said inhibitor is selected from the group consisting of an anti-fibrinolytic agent, a platelet concentrate, a coagulation factor concentrate and fresh frozen plasma.
number: 15
text: A pharmaceutical composition comprising an inhibitor as defined in any one of the preceding claims, and a pharmaceutically acceptable excipient.
number: 16
text: A pharmaceutical composition as defined in claim 15 for use in in the treatment or prevention of a hemorrhagic condition.
number: 17
text: A method of treating a hemorrhagic condition in a subject, preferably a human, comprising administering to the subject an effective amount of an inhibitor as defined in any one of claims 1 to 11, or the pharmaceutical composition of claim 15.
Office action: search_report, dated 2017-06-28
Rejection reasons: novelty_epc_54
inventive_step_epc_56
Prior art cited: ref_id: US5807715A
ref_type: patent
severity: background
ref_id: US4816567A
ref_type: patent
severity: background
ref_id: US4816397A
ref_type: patent
severity: background
ref_id: US5530101A
ref_type: patent
severity: background
ref_id: US5585089A
ref_type: patent
severity: background
ref_id: US5693761A
ref_type: patent
severity: background
ref_id: US5693762A
ref_type: patent
severity: background
ref_id: US6180370B1
ref_type: patent
severity: background
ref_id: EP0239400A2
ref_type: patent
severity: background
ref_id: WO9109967A1
ref_type: patent
severity: background
ref_id: US5225539A
ref_type: patent
severity: background
ref_id: EP0592106A1
ref_type: patent
severity: background
ref_id: EP0519596A1
ref_type: patent
severity: background
ref_id: US5565332A
ref_type: patent
severity: background
ref_id: US4444887A
ref_type: patent
severity: background
ref_id: US4716111A
ref_type: patent
severity: background
ref_id: WO9846645A2
ref_type: patent
severity: background
ref_id: WO9850433A2
ref_type: patent
severity: background
ref_id: WO9824893A2
ref_type: patent
severity: background
ref_id: WO9816654A1
ref_type: patent
severity: background
ref_id: WO9634096A1
ref_type: patent
severity: background
ref_id: WO9633735A1
ref_type: patent
severity: background
ref_id: WO9110741A1
ref_type: patent
severity: background
ref_id: WO9201047A1
ref_type: patent
severity: background
ref_id: US5413923A
ref_type: patent
severity: background
ref_id: US5625126A
ref_type: patent
severity: background
ref_id: US5633425A
ref_type: patent
severity: background
ref_id: US5569825A
ref_type: patent
severity: background
ref_id: US5661016A
ref_type: patent
severity: background
ref_id: US5545806A
ref_type: patent
severity: background
ref_id: US5814318A
ref_type: patent
severity: background
ref_id: US5885793A
ref_type: patent
severity: background
ref_id: US5916771A
ref_type: patent
severity: background
ref_id: US5939598A
ref_type: patent
severity: background
ref_id: US5658570A
ref_type: patent
severity: background
ref_id: US5681722A
ref_type: patent
severity: background
ref_id: US5693780A
ref_type: patent
severity: background
ref_id: WO2005123780A2
ref_type: patent
severity: background
ref_id: US7217797B2
ref_type: patent
severity: background
ref_id: US7361740B2
ref_type: patent
severity: background
ref_id: US7365168B2
ref_type: patent
severity: background
ref_id: US7217798B2
ref_type: patent
severity: background
ref_id: US2007280931A1
ref_type: patent
severity: background
ref_id: WO8601533A1
ref_type: patent
severity: background
ref_id: EP0392745A2
ref_type: patent
severity: background
ref_id: WO2005117984A2
ref_type: patent
severity: background
ref_id: US5219996A
ref_type: patent
severity: background
ref_id: EP0948544A1
ref_type: patent
severity: background
ref_id: - COUGHLIN SR., NATURE., vol. 407, 2000, pages 258 - 64
ref_type: npl
severity: background
ref_id: - SHAPIRO MJ ET AL., JBC, vol. 275, 2000, pages 25216 - 21
ref_type: npl
severity: background
ref_id: - NIESWANDT B ET AL., BLOOD, vol. 102, 2003, pages 449 - 61
ref_type: npl
severity: background
ref_id: - OFFERMANNS S., CIRCULATION RESEARCH, vol. 99, 2006, pages 1293 - 304
ref_type: npl
severity: background
ref_id: - NAKANISHI-MATSUI M ET AL., NATURE, vol. 404, 2000, pages 609 - 13
ref_type: npl
severity: background
ref_id: - CUNNINGHAM MA ET AL., J EXP MED, vol. 191, 2000, pages 455 - 62
ref_type: npl
severity: background
ref_id: - LUO S.-Z. ET AL., BLOOD, vol. 109, no. 2, 2007, pages 603 - 9
ref_type: npl
severity: background
ref_id: - NIESWANDT B ET AL., J THROMB HAEMOST, vol. 7, 2009, pages 206 - 9
ref_type: npl
severity: background
ref_id: - VARGA-SZABO D ET AL., J THROMB HAEMOST, vol. 7, 2009, pages 1057 - 66
ref_type: npl
severity: background
ref_id: - CANOBBIO I ET AL., CELLULAR SIGNALLING, vol. 16, 2004, pages 1329 - 44
ref_type: npl
severity: background
ref_id: - RAMAKRISHNAN V ET AL., PNAS, vol. 96, 1999, pages 13336 - 41
ref_type: npl
severity: background
ref_id: - KAHN ML ET AL., BLOOD, vol. 94, 1999, pages 4112 - 21
ref_type: npl
severity: background
ref_id: - DONG J-F ET AL., J BIOL CHEM., vol. 273, 1998, pages 31449 - 54
ref_type: npl
severity: background
ref_id: - RAVANAT C ET AL., BLOOD, vol. 89, 1997, pages 3253 - 62
ref_type: npl
severity: background
ref_id: - AZORSA DO ET AL., THROMBOSIS AND HAEMOSTASIS, vol. 81, 1999, pages 131 - 8
ref_type: npl
severity: background
ref_id: - KAHN ML ET AL., NATURE, vol. 394, 1998, pages 690 - 4
ref_type: npl
severity: background
ref_id: - NI H ET AL., BLOOD, vol. 98, 2001, pages 368 - 73
ref_type: npl
severity: background
ref_id: - MOOG S ET AL., BLOOD, vol. 98, 2001, pages 1038 - 46
ref_type: npl
severity: background
ref_id: - NONNE C ET AL., J THROMB HAEMOST, vol. 6, 2008, pages 210 - 2
ref_type: npl
severity: background
ref_id: - TATUSOVA ET AL., FEMS MICROBIOL. LETT., vol. 174, 1999, pages 247 - 250
ref_type: npl
severity: background
ref_id: - WAHL ET AL., J. NUCL. MED., vol. 24, 1983, pages 316
ref_type: npl
severity: background
ref_id: - HARLOW; LANE: "Antibodies, A Laboratory Manual", 1988, CSH PRESS
ref_type: npl
severity: background
ref_id: - MORRISON, SCIENCE, vol. 229, no. 4719, 1985, pages 1202 - 7
ref_type: npl
severity: background
ref_id: - OI ET AL., BIOTECHNIQUES, vol. 4, 1986, pages 214 - 221
ref_type: npl
severity: background
ref_id: - GILLIES ET AL., J. IMMUNOL. METHODS, vol. 125, 1985, pages 191 - 202
ref_type: npl
severity: background
ref_id: - RIECHMANN ET AL., NATURE, vol. 332, 1988, pages 323 - 7
ref_type: npl
severity: background
ref_id: - PADLAN, MOL IMMUNOL, vol. 28, 1991, pages 489 - 498
ref_type: npl
severity: background
ref_id: - STUDNICKA ET AL., PROT ENG, vol. 7, 1994, pages 805 - 814
ref_type: npl
severity: background
ref_id: - ROGUSKA ET AL., PNAS, vol. 91, 1994, pages 969 - 973
ref_type: npl
severity: background
ref_id: - JESPERS ET AL., BIOTECHNOLOGY, vol. 12, 1988, pages 899 - 903
ref_type: npl
severity: background
ref_id: - CANFIELD; MORRISON, J EXP MED., vol. 173, 1991, pages 1483 - 1491
ref_type: npl
severity: background
ref_id: - LUND ET AL., J IMMUNOL., vol. 147, 1991, pages 2657 - 2662
ref_type: npl
severity: background
ref_id: - HELLSTROM ET AL.: "Controlled Drag Delivery", 1987, pages: 623 - 53
ref_type: npl
severity: background
ref_id: - THORPE ET AL., IMMUNOL REV, vol. 62, 1982, pages 119 - 58
ref_type: npl
severity: background
ref_id: - DUBOWCHIK ET AL., PHARMACOLOGY AND THERAPEUTICS, vol. 83, 1999, pages 67 - 123
ref_type: npl
severity: background
ref_id: - "Poly(ethyleneglycol) Chemistry, Biotechnical and Biomedical Applications", 1992, PLENUM PRESS
ref_type: npl
severity: background
ref_id: - "Poly(ethyleneglycol) Chemistry and Biological Applications", 1997, AMERICAN CHEMICAL SOCIETY
ref_type: npl
severity: background
ref_id: - "Bioconjugation Protein Coupling Techniques for the Biomedical Sciences", 1998, GROVE PUBLISHERS
ref_type: npl
severity: background
ref_id: - CHAPMAN, ADVANCED DRUG DELIVERY REVIEWS, vol. 54, 2002, pages 531 - 545
ref_type: npl
severity: background
ref_id: - "siRNA Design: Methods and Protocols", 2012
ref_type: npl
severity: background
ref_id: - "De novo Molecular Design", 2013
ref_type: npl
severity: background
ref_id: - "The Aptamer Handbook: Functional Oligonucleotides and Their Applications", 2006
ref_type: npl
severity: background
ref_id: - "Pharmaceutical Formulation Development of Peptides and Proteins", 2000, TAYLOR & FRANCIS
ref_type: npl
severity: background
ref_id: - KIBBE ET AL.: "Handbook of Pharmaceutical Excipients", 2000, PHARMACEUTICAL PRESS
ref_type: npl
severity: background
ref_id: - A. GENNARO: "Remington: The Science and Practice of Pharmacy", 2000, LIPPINCOTT, WILLIAMS, & WILKINS
ref_type: npl
severity: background
ref_id: - "Pharmaceutical Dosage Forms and Drug Delivery Systems", 1999, LIPPINCOTT, WILLIAMS, & WILKINS
ref_type: npl
severity: background
ref_id: - "Handbook of Pharmaceutical Excipients", 2000, AMER. PHARMACEUTICAL ASSOC
ref_type: npl
severity: background
ref_id: - "Remington's Pharmaceutical Sciences", 1980
ref_type: npl
severity: background
ref_id: - BUSTELO XR ET AL., BIOESSAYS, vol. 29, 2007, pages 356 - 70
ref_type: npl
severity: background
ref_id: - PLEINES I ET AL., BLOOD, vol. 119, 2012, pages 1054 - 63
ref_type: npl
severity: background
ref_id: - NIESWANDT B ET AL., BLOOD, vol. 96, 2000, pages 2520 - 7
ref_type: npl
severity: background
ref_id: - BERGMEIER W ET AL., BLOOD, vol. 95, 2000, pages 886 - 93
ref_type: npl
severity: background
ref_id: - KAHN M. ET AL., BLOOD, vol. 94, 1999, pages 4112 - 21
ref_type: npl
severity: background
ref_id: - HOLTKOTTER O. ET AL., J BIOL CHEM., vol. 277, no. 13, 2002, pages 10789 - 94
ref_type: npl
severity: background
ref_id: - PLEINES I. ET AL., BLOOD, vol. 119, 2012, pages 1054 - 63
ref_type: npl
severity: background
ref_id: - NIESWANDT B ET AL., J EXP MED., vol. 193, 2001, pages 459 - 69
ref_type: npl
severity: background
ref_id: - MAY F ET AL., BLOOD, vol. 114, 2009, pages 3464 - 72
ref_type: npl
severity: background
ref_id: WO9502054A2
ref_type: patent
severity: background
ref_id: - H. NI ET AL: "Increased thrombogenesis and embolus formation in mice lacking glycoprotein V", BLOOD, vol. 98, no. 2, 15 July 2001 (2001-07-15), US, pages 368 - 373, XP055254460, ISSN: 0006-4971, DOI: 10.1182/blood.V98.2.368
ref_type: npl
severity: background
ref_id: - RAMAKRISHNAN V ET AL: "INCREASED THROMBIN RESPONSIVENESS IN PLATELETS FROM MICE LACKING GLYCOPROTEIN V", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, vol. 96, no. 23, 1 January 1999 (1999-01-01), pages 13336 - 13341, XP000869655, ISSN: 0027-8424, DOI: 10.1073/PNAS.96.23.13336
ref_type: npl
severity: background
ref_id: - S. MOOG: "Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation", BLOOD, vol. 98, no. 4, 15 August 2001 (2001-08-15), pages 1038 - 1046, XP055048230, ISSN: 0006-4971, DOI: 10.1182/blood.V98.4.1038
ref_type: npl
severity: background
ref_id: - AZORSA D O ET AL: "Measurement of GPV released by activated platelets using a sensitive immunocapture ELISA--its use to follow platelet storage in transfusion", THROMBOSIS AND HAEMOSTASIS, SCHATTAUER GMBH, DE, vol. 81, no. 1, 1 January 1999 (1999-01-01), pages 131 - 138, XP002754916, ISSN: 0340-6245
ref_type: npl
severity: background
ref_id: - KINCHINGTON P R ET AL: "THE GLYCOPROTEIN PRODUCTS OF VARICELLA-ZOSTER VIRUS GENE 14 AND THEIR DEFECTIVE ACCUMULATION IN A VACCINE STRAIN (OKA)", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 64, no. 9, 1 July 1990 (1990-07-01), pages 4540 - 4548, XP009000474, ISSN: 0022-538X
ref_type: npl
severity: background
ref_id: - NORIHIDE SATO ET AL: "Characterization of Monoclonal Antibodies Against Mouse and Rat Platelet Glycoprotein V (CD42d)", HYBRIDOMA, vol. 19, no. 6, 1 December 2000 (2000-12-01), US, pages 455 - 461, XP055265469, ISSN: 0272-457X, DOI: 10.1089/027245700750053940
ref_type: npl
severity: background
ref_id: - LANZA F ET AL: "CLONING AND CHARACTERIZATION OF THE GENE ENCODING THE HUMAN PLATELET GLYCOPROTEIN V", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 268, no. 28, 5 October 1993 (1993-10-05), pages 20801 - 20807, XP000867216, ISSN: 0021-9258
ref_type: npl
severity: background
ref_id: - KUNISHIMA SHINJI ET AL: "Further characterization of anti-platelet monoclonal antibody HPL5 as anti-glycoprotein V antibody", ACTA HAEMATOLOGICA, S. KARGER, BASEL, CH, vol. 115, no. 1-2, 1 January 2006 (2006-01-01), pages 128 - 130, XP009189540, ISSN: 0001-5792
ref_type: npl
severity: background
ref_id: WO9502054
ref_type: patent
severity: background
ref_id: - H. NI ET AL, "Increased thrombogenesis and embolus formation in mice lacking glycoprotein V", BLOOD, US, (20010715), vol. 98, no. 2, doi:10.1182/blood.V98.2.368, ISSN 0006-4971, pages 368 - 373, XP055254460 [Y] 1-17 * abstract figures *
ref_type: npl
severity: obviousness
ref_id: - RAMAKRISHNAN V ET AL, "INCREASED THROMBIN RESPONSIVENESS IN PLATELETS FROM MICE LACKING GLYCOPROTEIN V", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, US, (19990101), vol. 96, no. 23, doi:10.1073/PNAS.96.23.13336, ISSN 0027-8424, pages 13336 - 13341, XP000869655 [Y] 1-17 * abstract figures *
ref_type: npl
severity: obviousness
ref_id: - S. MOOG, "Platelet glycoprotein V binds to collagen and participates in platelet adhesion and aggregation", BLOOD, (20010815), vol. 98, no. 4, doi:10.1182/blood.V98.4.1038, ISSN 0006-4971, pages 1038 - 1046, XP055048230 [X] 15 * abstract pages 1038-139 figures * [Y] 1-14,16,17
ref_type: npl
severity: novelty_destroying
ref_id: - AZORSA D O ET AL, "Measurement of GPV released by activated platelets using a sensitive immunocapture ELISA--its use to follow platelet storage in transfusion", THROMBOSIS AND HAEMOSTASIS, SCHATTAUER GMBH, DE, (19990101), vol. 81, no. 1, ISSN 0340-6245, pages 131 - 138, XP002754916 [X] 15 * abstract pages 132-133 *
ref_type: npl
severity: novelty_destroying
ref_id: - KINCHINGTON P R ET AL, "THE GLYCOPROTEIN PRODUCTS OF VARICELLA-ZOSTER VIRUS GENE 14 AND THEIR DEFECTIVE ACCUMULATION IN A VACCINE STRAIN (OKA)", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, (19900701), vol. 64, no. 9, ISSN 0022-538X, pages 4540 - 4548, XP009000474 [A] 1-17 * abstract *
ref_type: npl
severity: background
ref_id: - NORIHIDE SATO ET AL, "Characterization of Monoclonal Antibodies Against Mouse and Rat Platelet Glycoprotein V (CD42d)", HYBRIDOMA, US, (20001201), vol. 19, no. 6, doi:10.1089/027245700750053940, ISSN 0272-457X, pages 455 - 461, XP055265469 [A] 1-17 * abstract figures *
ref_type: npl
severity: background
ref_id: - LANZA F ET AL, "CLONING AND CHARACTERIZATION OF THE GENE ENCODING THE HUMAN PLATELET GLYCOPROTEIN V", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, (19931005), vol. 268, no. 28, ISSN 0021-9258, pages 20801 - 20807, XP000867216 [A] 1-17 * abstract figures *
ref_type: npl
severity: background
ref_id: - KUNISHIMA SHINJI ET AL, "Further characterization of anti-platelet monoclonal antibody HPL5 as anti-glycoprotein V antibody", ACTA HAEMATOLOGICA, S. KARGER, BASEL, CH, (20060101), vol. 115, no. 1-2, ISSN 0001-5792, pages 128 - 130, XP009189540 [A] 1-17 * 128-129 *
ref_type: npl
severity: background
Final disposition: pending (2017-06-28)